Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC
Status:
Terminated
Trial end date:
2020-04-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the ability of alvimopan to reduce the time to
return of bowel function in patients undergoing cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy. Half of the participants will receive alvimopan or and half
will receive placebo immediately before and for up to seven days after surgery.